Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.68)
# 751
Out of 4,893 analysts
140
Total ratings
45.14%
Success rate
8.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $23.71 | +174.15% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $0.87 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $33.03 | +51.38% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $6.41 | +95.01% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $66.14 | +42.12% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $12.02 | +66.39% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $112.48 | +92.92% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $5.27 | +51.80% | 11 | Mar 7, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $21 | $9.77 | +114.94% | 16 | Mar 4, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $41.10 | +77.62% | 9 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.10 | +287.10% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $3.80 | +97.37% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.70 | +1,042.86% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $3.32 | +1,692.17% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $1.38 | +14,247.83% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $23.71
Upside: +174.15%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.87
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $33.03
Upside: +51.38%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $6.41
Upside: +95.01%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $66.14
Upside: +42.12%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $12.02
Upside: +66.39%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $112.48
Upside: +92.92%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $5.27
Upside: +51.80%
Avadel Pharmaceuticals
Mar 4, 2025
Reiterates: Buy
Price Target: $21
Current: $9.77
Upside: +114.94%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $41.10
Upside: +77.62%
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $3.10
Upside: +287.10%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $3.80
Upside: +97.37%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.70
Upside: +1,042.86%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $3.32
Upside: +1,692.17%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $1.38
Upside: +14,247.83%